CIP
ALNY icon

Convergence Investment Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Convergence Investment Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,307
Closed -$596K – 246
2025
Q3 		$596K Sell
1,307
-952
-42% -$388K 0.13% 192
2025
Q2 		$737K Buy
+2,259
New +$625K 0.19% 170
2024
Q4 		– Sell
-1,513
Closed -$416K – 254
2024
Q3 		$416K Buy
+1,513
New +$394K 0.11% 184

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Convergence Investment Partners's ALNY Position: Q4 2025 in Review

Convergence Investment Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 1,307 shares — an estimated $596K sold.

Convergence Investment Partners first reported a position in ALNY in Q3 2024 and held it in 3 quarters. The position peaked at $737K in Q2 2025. 851 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

  • Convergence Investment Partners reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Convergence Investment Partners sold 1,307 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $596K.
  • Convergence Investment Partners first reported a position in Alnylam Pharmaceuticals in Q3 2024 and held it in 3 quarters.
  • Convergence Investment Partners's Alnylam Pharmaceuticals position peaked at $737K in Q2 2025.
  • 851 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on Convergence Investment Partners's 13F filing for Q4 2025, filed 5 Feb 2026.